Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 141

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 141
---
above, we are also exploring other pre-clinical and clinical studies of the combination of Alpha DaRT and systemic therapies, including
through pre-clinical testing at our pre-clinical GLP-certified animal laboratory in Jerusalem.

Summary of Our Pre-Clinical Findings

We consider pre-clinical research
as a source of strong and ongoing support for our core thesis and for potential expansion into a wide range of proposed indications. To
that end, we continue to invest, both internally and with leading universities and academic centers around the world, in conducting robust
pre-clinical research with particular focus on potential supra-additive combinations of Alpha DaRT with other therapies such as immunotherapies
and chemotherapies. Among other things, we have completed construction of our own pre-clinical laboratory at our headquarters in Jerusalem,
Israel, which has received the necessary certifications to initiate pre-clinical studies, to facilitate our own examination of such combinations.

The extensive pre-clinical
research conducted on Alpha DaRT has generally focused on three core areas: (1) evaluating the potency of Alpha DaRT in destroying tumors,
measured across a broad range of cell lines, (2) evaluating combinational treatments with standard of care / FDA approved therapies such
as chemotherapy and antiangiogenic agents, and (3) evaluating the immunostimulatory potential of the Alpha DaRT and optimizing the combination
of Alpha DaRT and immunotherapy. Pre-clinical research, including both in vitroand in vivoexperiments as well as physical,
biological and computational modeling of the diffusion or biokinetic properties of Alpha DaRT, have led to the publication of 26 articles
in peer-reviewed journals.

Alpha DaRT is Designed to Efficiently Destroy
a Tumor

Pre-clinical studies were
performed in vitroand in vivowith mouse tumor models and human derived tumors, to evaluate the diffusion properties and
potential therapeutic activity of Alpha DaRT:

Summary of Pre-Clinical Studies

  Histology                    Murine Cells in       Human Cells in            
                               Mice or in Vitro      Athymic Mice or in Vitro  
  Skin SCC                     X                     X                         
 ───────────────────────────────────────────────────────────────────────────────
  Lung SCC                                           X                         
  HNSCC                                              X                         
  Lung Adenocarcinoma          X                     X                         
  Pancreas Adenocarcinoma      X                     X                         
  Prostate Adenocarc